Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday. They currently have a $46.27 price target on the biopharmaceutical company’s stock. Vetr‘s target price points to a potential upside of 11.90% from the stock’s previous close. […]
